𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

✍ Scribed by Keith T. Flaherty; James P. Stevenson; Stephen M. Hahn; Maryann Redlinger; Peter J. O'Dwyer

Publisher
Springer
Year
2003
Tongue
English
Weight
178 KB
Volume
52
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequential combination chemotherapy in p
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma : Carboplatin and gemcitabine followed by paclitaxel
✍ Martin J. Edelman; David R. Gandara; Derrick H. M. Lau; Primo Lara; I. Jun Laude πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 98 KB πŸ‘ 2 views

## Background: The objective of this phase ii study was to evaluate the concept of sequential chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma (nsclc) by the administration of carboplatin plus gemcitabine followed by of paclitaxel. ## Methods: Patients with sta

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi